Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Cost of Revenue (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Cost of Revenue for 15 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 12.82% year-over-year to $1.4 million, compared with a TTM value of $6.1 million through Oct 2025, down 12.9%, and an annual FY2025 reading of $6.1 million, down 12.9% over the prior year.
  • Cost of Revenue was $1.4 million for Q4 2025 at Pharma-Bio Serv, up from $1.4 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $4.1 million in Q4 2021 and bottomed at $1.4 million in Q3 2025.
  • Average Cost of Revenue over 5 years is $2.7 million, with a median of $3.0 million recorded in 2023.
  • The sharpest move saw Cost of Revenue rose 18.95% in 2022, then tumbled 45.31% in 2024.
  • Year by year, Cost of Revenue stood at $4.1 million in 2021, then decreased by 13.88% to $3.5 million in 2022, then dropped by 24.4% to $2.7 million in 2023, then tumbled by 39.79% to $1.6 million in 2024, then fell by 12.82% to $1.4 million in 2025.
  • Business Quant data shows Cost of Revenue for PBSV at $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.6 million in Q2 2025.